Canadian Respiratory Journal / 2017 / Article / Tab 3

Research Article

Readability and Suitability of COPD Consumer Information

Table 3


Advair DiskusDPIGlaxoSmithKline
AiromirMDIValeant Canada LP
Anoro ElliptaDPIGlaxoSmithKline
Apo-Salvent CFC FreeMDIApotex
Atrovent HFAMDIBoehringer Ingelheim
Breo ElliptaDPIGlaxoSmithKline
Bricanyl TurbuhalerDPIAstraZeneca
Combivent RespimatSMIBoehringer Ingelheim
Duaklir GenuairDPIAstraZeneca
Foradil AerolizerDPINovartis Pharmaceuticals
Incruse ElliptaDPIGlaxoSmithKline
Inspiolto RespimatSMIBoehringer Ingelheim
Novo-Salbutamol HFAMDITeva Canada
Onbrez BreezhalerDPINovartis Pharmaceuticals
Salbutamol HFAMDISanis Health
Seebri BreezhalerDPINovartis Pharmaceuticals
Serevent Diskhaler DiskDPIGlaxoSmithKline
Serevent DiskusDPIGlaxoSmithKline
SpirivaDPI (handihaler)Boehringer Ingelheim
Spiriva RespimatSMIBoehringer Ingelheim
Striverdi RespimatSMIBoehringer Ingelheim
Symbicort TurbuhalerDPIAstraZeneca
Tudorza GenuairDPIAstraZeneca
Ultibro BreezhalerDPINovartis Pharmaceuticals
Ventolin DiskusDPIGlaxoSmithKline
Ventolin HFAHFAGlaxoSmithKline

Generic products; only 100/25 mcg/dose indicated in COPD; approved by Health Canada but not currently marketed; MDI: metered dose inhaler; DPI: dry powdered inhaler; SMI: soft mist inhaler.

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.